Berlin Cures' failed Long COVID clinical trial yields lessons on study design
- Condition
- Long COVID
- At worst
- Severe (mostly bedbound)
- Ill for
- Not stated
- Published
- Jul 2025
Summary
Shayna Bhalla received BC 007 (rovunaptabin) infusions as part of the Berlin Cures Long COVID trial, though the article does not give the specific dose, frequency, or duration of infusions. She had lived with Long COVID for years, with fatigue, headaches and neurological issues. During the trial her symptoms dramatically receded and she said she had "regained life," resuming university classes and daily activities, though not fully back to her pre-COVID baseline. When Berlin Cures announced in November 2024 that the trial had failed, she said she felt "back at zero," indicating her gains were not sustained once the drug was no longer available.
What they credit
Credits Biologics & antibodies, BC 007 / rovunaptabin.
Symptoms mentioned
Symptoms: Headaches & migraine, Pain & fibromyalgia.
Similar stories
-
Berlin Cures' failed trial (Emma)
Emma took part in the same Berlin Cures trial of BC 007 (rovunaptabin), though the article does not specify her dose or whether she received the active drug or placebo, nor how severe or long-standing her Long COVID was. She reported that her symptoms…
-
Berlin Cures? Could BC 007 Help With Long COVID and ME/CFS? (glaucoma)
This long-COVID patient, who also had glaucoma, received a single infusion of BC 007, though the page does not give the dose or infusion length for this case. Her long COVID symptoms cleared up afterward, an outcome that helped prompt Berlin Cures' broader…
-
Berlin Cures? Could BC 007 Help With Long COVID and ME/CFS? (exerciser)
This avid exerciser received a single 75-minute BC 007 IV infusion with three days of hospital monitoring, after long COVID had left the person bedridden with episodes of temporary paralysis and unable to follow conversations. The infusion produced a marked,…
-
Berlin Cures? Could BC 007 Help With Long COVID and ME/CFS? (skier)
This cross-country skier and former Ironman athlete received a single 75-minute IV infusion of the investigational drug BC 007, with three days of hospital monitoring afterward, months after a COVID infection had left him severely debilitated, disoriented…